Torrent Pharma trying to boost Unichem’s low-growth hypertension drug
21/07/2018
Mumbai: Torrent Pharmaceutical’s acquisition of Unichem’s branded generics portfolio may have boosted the firm’s domestic market performance, however, there are some low-growth areas for the Ahmedabad-headquartered firm to work on.
According to market data, a key anti-hypertension molecule that came in through the acquisition is in low-growth trajectory as the domestic market has shifted to newer molecules.
Losartan, an anti-hypertension drug, in which Unichem enjoyed around 37-38 per cent market share, has hardly seen any growth in the past five years.
In June, there was a decline of 3.6 per cent in the overall market value for the drug, according to the data sourced from market research firm AIOCD AWACS.
Losartan, an early generation anti-hypertension drug, accounts for nearly 20 per cent of the acquired portfolio.
Edelweiss has noted the anti-hypertension market has shifted towards another molecule, Telmisartan, which is considered more efficacious. Torrent’s competitors such as Sun Pharmaceuticals and Mankind Pharma have also seen decline in growth in Losartan and have shifted focus to their respective Telmisartan brands.
“Given that the overall anti-hypertensive market is growing at a CAGR of 11 per cent, Losartan will in fact be a key contributor to our anti-hypertension portfolio. Losartan continues to have highest number of approval across various indications among the Angiotensin II receptor blockers (ARBs).
Leveraging this will facilitate significant market share expansion opportunities for Losartan,” said a Torrent Pharma spokesperson.
Share This Story |
|
Comment On This Story |
|
|
|
|